Redeye updates on Gentoo Media post Q4-results where we see continued growth potential in the coming...
Strong Q4 organic growth and double-digit '25 target 10-8% EPS downgrades for '25e-'27e Trading well...
CirChem har publicerat bolagets delårsrapport för det fjärde kvartalet 2024.
24% organic sales growth y-o-y Improved gross margin due to pricing and mix Opex flat y-o-y leads to...
Redeye gives a short comment on today’s news that IRLAB extends its runway following “extended and e...
Justerat för jämförelsestörande poster kom rapporten in över vår prognos.
Net sales of SEK46m were in line with our estimates, while EBIT exceeded expectations by SEK10m.
Vaisala's Q4 results aligned with the preliminary figures the company disclosed in January.
Strong organic growth in Q4 at 18%, albeit 2% below ABGSCe Q4 adj.
Redeye states that CoinShares’ Q4 2024 report was strong, with beats across all segments.
Extended Fenja loan (SEK 55m) with new SEK 20m option New shareholder loan (SEK 22.
CoinShares reported its best quarter ever on AUM Beat on Capital Markets, miss on Asset Management U...
Net sales SEK 202m, +7% vs ABGSCe and Factset cons.
Rec. PTP adj. -13% vs ABGSCe Financial net impacted by one-offs Cons to lower rec.
Redeye updates its estimates and fair value range following Arise’s Q4 2024 report, which marked the...
Redeye provides an update following Corline’s Q4 2024 report.
We lower our 2025-26 sales estimates by 4%, mainly driven by Germany.
Q4 below, Q1 likely better Pulp prices rising amid price hikes Fair value range: SEK 9-16/sh Q4 bel...
Another quarter of y-o-y margin improvement Margin-driven EBITA upgrades of 6-4% for '25e-'26e Share...
Minor positive revisions following solid Q4 Growing CEPS 40% in 2025e '25e P/CEPS ~13x (25% below se...